Sweden · Delayed Price · Currency is SEK Medicover AB Earnings Call Transcripts
Fiscal Year 2026
-
Double-digit organic revenue growth and margin expansion continued, with strong results in Diagnostics and India, improved cash flow, and leverage below 3x. Strategic options for the Indian business are under review, and midterm financial targets remain on track.
-
Q1 2026 delivered strong organic growth of 10.3% and margin expansion, with revenue at €624.2 million and adjusted EBITDA up 15.4%. India and Diagnostic Services led growth, while weather and geopolitical headwinds were effectively managed.
-
Strong organic growth, margin expansion, and disciplined investment have positioned the group for ambitious 2028 targets, with double-digit revenue and EBITDA growth expected. Key markets—Poland, Germany, Romania, and India—drive performance, supported by digital innovation and operational leverage.
Fiscal Year 2025
-
Double-digit revenue and profit growth in Q4 and FY 2025, with margin expansion and strong cash flow, driven by robust demand in core markets and successful integration of acquisitions. Achieved all three-year financial targets and set ambitious new goals for 2028.
-
Q3 saw strong organic growth, margin expansion, and robust cash flow, with both healthcare and diagnostics segments performing well. Guidance for the full year is unchanged, with expectations to beat revenue and EBITDA targets, despite some consumer caution and operational headwinds.
-
Q2 delivered 17% revenue growth, strong margin expansion, and tripled net profit, driven by organic growth across all markets and successful integration of recent acquisitions. Outlook remains positive, with targets expected to be exceeded and leverage to decline.
-
The group reported strong Q1 growth, driven by expanded capacity, robust demand, and strategic acquisitions. It is on track to exceed 2025 financial targets, focusing on deepening market penetration in core countries and enhancing profitability through operational efficiency and innovation.
-
Record Q1 results with strong organic growth, margin expansion, and cash flow, surpassing 2025 financial targets on an annualized basis. Poland and diagnostics led performance, while India rebounded after a weak quarter. Two strategic acquisitions are expected to be highly accretive.
Fiscal Year 2024
-
Delivered strong double-digit organic growth and margin expansion in both divisions for Q4 and FY2024, with Poland, Germany, and Romania leading performance. Cash flow and free cash flow surged, dividend increased 25%, and guidance for 2025 remains confident, with India and diagnostics expected to accelerate.
-
Q3 saw robust organic revenue growth of 17.4% and record operating cash flow, with both Healthcare and Diagnostic Services contributing to margin expansion. Management remains confident in meeting 2025 targets, expects continued strong cash generation, and is mitigating German reimbursement risks.
-
Q2 2024 saw 20% revenue growth (16% organic), strong cash generation, and margin expansion across divisions. Poland, Germany, and Romania led growth, while India is set to rebound. Confident in meeting 2025 targets, with continued investment and stable leverage.